OncoMatch/Clinical Trials/NCT06215976
The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer
Is NCT06215976 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies Metformin Hydrochloride 500 MG for muscle-invasive bladder carcinoma.
Treatment: Metformin Hydrochloride 500 MG — The goal of this clinical trial is to evaluate the protective effect of metformin on nephrotoxicity of cisplatin in patients with bladder cancer. The main questions it aims to answer are: * To determine protective effect of metformin on structural and functional kidney injury caused by cisplatin in patients with bladder cancer. * To evaluate the safety of combining cisplatin and metformin on patients with bladder cancer
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Urothelial Carcinoma
Demographics
Prior therapy
Lab requirements
Kidney function
stable renal function: eGFR is above 60 ml/min/1.73 m2; unstable renal function (increase in serum creatinine of 0.3 mg/dL or greater suddenly in 48 hours) excluded
Patients with stable renal function: eGFR is above 60 ml/min/1.73 m2; Unstable renal function (defined as an increase in serum creatinine of 0.3 mg/dL or greater suddenly in 48 hours according to the acute kidney injury network (AKIN) classification [excluded])
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06215976 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages